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DNA vaccination with naked DNA encoding MCP-1 and
RANTES protects against renal injury in adriamycin nephropa-
thy.
Background. We have previously shown that monocyte
chemoattractant protein-1 (MCP-1) and regulated upon activa-
tion, normal T-cell expressed and secreted (RANTES) are sig-
nificantly increased in renal cortex in adriamycin nephropathy.
In this study, we tested the effect of DNA vaccination encoding
the C-C chemokines MCP-1 and RANTES in a rat model of
adriamycin nephropathy.
Methods. Both reverse transcription-polymerase chain re-
action (RT-PCR) products of MCP-1 and RANTES used as
constructs were cloned into a pTarget vector for naked DNA
vaccination. Two hundred micrograms of DNA was injected
into the tibialis anterior muscle four times at weekly intervals.
One week after the last DNA vaccination, rats received adri-
amycin. All animals were sacrificed 4 weeks after adriamycin ad-
ministration. Changes in renal function and histologic features
were assessed. Enzyme-linked immunosorbent assay (ELISA)
and Western blot were used for autoantibody determination.
Antibody specificity was assessed in in vitro transmigration
assays.
Results. Chemokine DNA vaccination significantly reduced
proteinuria (P < 0.05) and ameliorated creatinine clearance
(P < 0.05) at 2, 3, and 4 weeks after adriamycin administra-
tion. Morphometric analysis showed less glomerular sclerosis
(P < 0.001) and interstitial infiltrates (P < 0.005) in chemokine
DNA vaccination group compared with control groups. Anti-
MCP-1 and RANTES autoantibodies were detected in higher
concentrations in chemokine DNA vaccinated rats than in con-
trol rats (P < 0.001) and serum from vaccinated rats blocked
T-cell transmigration to MCP-1 and RANTES.
Conclusion. In this study, we have shown that naked DNA
vaccination against MCP-1 and RANTES ameliorates the
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progression of renal disease in the rat adriamycin nephropa-
thy model of chronic proteinuric renal disease. The protec-
tive mechanism may involve the production of autoantibodies
against MCP-1 and RANTES.
Adriamycin nephropathy is induced in both rats and
mice by a single intravenous injection of adriamycin,
which is directly toxic to the kidney, leading to chronic
proteinuric renal disease similar to human focal segmen-
tal glomerulosclerosis (FSGS) [1]. The pathologic fea-
tures of adriamycin nephropathy are severe nephrotic
syndrome, focal glomerular sclerosis, and tubular in-
jury with massive mononuclear cell infiltrates composed
largely of macrophages and T cells [1–3]. Our previous
studies showed that overt proteinuria appeared shortly
after adriamycin injection and was maintained through-
out the experiment. Glomerular vacuolation and focal
glomerular sclerosis were apparent by week 4 and ex-
tensive focal and even global glomerular sclerosis by
week 6. Tubulointerstitial infiltrates were dominated by
macrophages at week 2, and later by accumulation of both
CD4+ and CD8+ T cells [1–3].
Renal infiltration by macrophages and T cells into the
kidney is dependent on chemokines, released by injured
resident kidney cells. These chemokines promote the re-
cruitment and activation of infiltrating cells in diseased
kidney. Several studies have characterized the increased
expression of chemokines both in human renal diseases
and in animal models of acute glomerular or tubulointer-
stitial diseases [4, 5]. The selective role of chemokines
in the trafficking of macrophages and T cells to sites
of inflammation may be crucial to the evolution of re-
nal injury since chemokine expression has been found
to correlate with the local infiltration of effector cells
and renal damage [5]. In vivo studies in experimental
animals and humans have suggested a pivotal role for
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two chemokines, monocyte chemoattractant protein-1
(MCP-1) and regulated upon activation, normal T-cell
expressed and secreted (RANTES), in producing renal
inflammation. We have shown up-regulation of these
chemokines (MCP-1 and RANTES) in rat renal tubules
in adriamycin nephropathy, and tubular chemokine pro-
duction in response to urinary protein and albumin
[6, 7]. The pathogenic effect of MCP-1 and RANTES
in various renal diseases has been demonstrated by ma-
nipulation of their expression [8]. For example, over-
expression of RANTES in the lpr MRL mouse model
worsened interstitial nephritis [9]. In addition, a study in
MCP-1–deficient mice with nephrotoxic serum nephritis
demonstrated that MCP-1 recruited macrophages into
the kidney and promoted macrophage-mediated renal
tubular injury [10]. Interference with chemokine path-
ways has been shown to be protective in several mod-
els of renal injury. Treatment with MCP-1 antibodies
reduced proteinuria and monocyte infiltration in rat
nephrotoxic serum nephritis [11] and abrogated crescent
formation and leukocyte infiltration in murine nephro-
toxic nephritis [12]. Mice treated with the RANTES
antagonist Met-RANTES had reduced proteinuria, and
T-cell and macrophage infiltration in nephrotoxic serum
nephritis [12]. Blockade of the chemokine receptor CCR5
by amino-oxypentane (AOP) RANTES ameliorated ex-
perimental glomerulonephritis [13], and antisense was
used to inhibit MCP-1 in the Goodpastures rat model
[14]. Taken together, these studies in different immuno-
logic models of renal disease suggest pathogenic roles for
MCP-1 and RANTES in the recruitment of leukocytes
into the interstitium and the resulting tissue damage in
chronic proteinuric renal disease, and the potential of
their blockade as a therapeutic strategy [8].
The ability to alter trafficking of inflammatory and im-
mune cells in the context of immune-mediated damage
against organ-specific inflammation has been shown to
be crucial in nonrenal diseases such as experimental aller-
gic encephalomyelitis (EAE), the mouse model of multi-
ple sclerosis, and in diabetes and transplantation [15–17].
The development of drugs that influence the trafficking
of T cells such as FTY-720 and their use in immunosup-
pression suggest that the chemokine pathways are an ex-
citing novel area to target in prevention of organ specific
immune damage as found in proteinuric renal disease
[18, 19].
In this study, we tested the effect of a novel therapeu-
tic approach, that of DNA vaccination targeting the C-C
chemokines MCP-1 and RANTES in a rat adriamycin
nephropathy, a well characterized model of chronic pro-
teinuric renal disease. We sought to confirm pathogenic
roles for MCP-1 and RANTES, to examine the efficacy
of a novel form of therapy for renal disease, and to inves-
tigate the protective mechanisms of DNA vaccination in
this model.
METHODS
Experimental design and induction of
adriamycin nephropathy
Inbred male Wistar rats were obtained from the Ani-
mal Care Facility, Westmead Hospital, Sydney, Australia.
Rats weighing 130 to 180 g at the age of 5 to 6 weeks were
used in all experiments. Adriamycin nephropathy was in-
duced as described previously [2]. Rats received a single
intracardiac injection of adriamycin (6.9 mg/kg) (David
Bull Laboratories, Victoria, Australia). Rats were kept
in individual cages and allowed free access to water and
regular rat chow ad libitum.
Rats were divided into five groups: (1) DNA vacci-
nation group (DV), DNA vaccination against MCP-1
and RANTES in adriamycin nephropathy (N = 5); (2)
DNA vaccination control group (DV ctrl), DNA vacci-
nation with empty pTarget vector as a control for vaccina-
tion in adriamycin nephropathy (N = 5); (3) adriamycin
nephropathy group (AN), adriamycin nephropathy in-
jection with adriamycin alone (N = 3); (4) phosphate-
buffered saline group (PBS), phosphate-buffered saline
(PBS) injection with PBS only in normals as a control
for adriamycin (N = 3); and (5) DNA vaccination alone
group (DV alone), DNA vaccination against MCP-1 and
RANTES in normal rats (N = 3).
Blood from each animal was collected weekly. At
4 weeks after adriamycin administration, rats were sac-
rificed and each kidney was divided into three portions:
one portion was placed in formalin, one in embedding 22-
oxacalcitriol (OCT) compound to be snap frozen for his-
tologic examination and another portion was snap frozen
and used for reverse transcription-polymerase chain re-
action (RT-PCR) analysis. The blood and spleen from
each animal were also harvested. The protocol was ap-
proved by the conjoint Animal Ethics Committee of the
Children’s Medical Research Institute and the Children’s
Hospital at Westmead.
DNA vaccination
RNA was isolated from the diseased kidney of adri-
amycin nephropathy rats as previously described [20] and
reverse transcribed into cDNA. Oligonucleotide primers
used for the MCP-1 and RANTES genes were those de-
scribed [21] as follows: MCP-1 sense 5′-ATGCAGGT
CTCTTGTCACGCTTCTGGGC-3 and antisense 5′-CT
AGTTCTCTGTCATACTGGTCAC-3′; and RANTES
sense 5′-ATGAAGATCTCTGCAGCTGCATCC-3 and
antisense ′-CTAGCTCATCTCCAAATAGTTG-3.
All forward primers were designed to include an in-
frame ATG. cDNA was amplified by PCR with primers
specific for rat MCP-1 and RANTES. The PCR cycle
profile consisted of denaturation at 95◦C for 1minute,
annealing at 55◦C for 1 minute, and extension at 72◦C
for 1 minute for 35 cycles in a DNA thermal cycler
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(Perkin-Elmer, Wellesley, MA, USA). Amplified PCR
products were cloned into the pTarget plasmid DNA
(Promega, Madison, WI, USA) according to the manu-
facturer’s instructions. Plasmid DNA from colonies with
an insert was sequenced to confirm the insertion of the
correct gene from Genbank with the ATG in frame.
Large-scale preparation of plasmid DNA was performed
using the Mega prep kit (Qiagen, Hilden Germany).
For DNA vaccination, animals were pretreated with
0.75% bupivacaine (1 lL/g body weight) (Sigma Chemi-
cal Co., St. Louis, MO, USA) by injection into the tibialis
anterior muscle 1 week before the first vaccination. This
is known to enhance the efficiency of DNA vaccination.
Two hundred micrograms of DNA was injected into the
same site four times at weekly intervals. One week af-
ter the fourth DNA vaccination, rats were treated with
adriamycin. Rats received a booster injection of DNA
vaccine 1 week after adriamycin administration.
Assessment of renal function
Sixteen-hour urine samples were collected in metabolic
cages weekly after adriamycin administration. Urine pro-
tein concentrations were determined by colorimetric
assay (Bio-Rad, Oakland, CA, USA). Blood and urine
creatinine were analyzed at the Institute of Clinical
Pathology and Medical Research as previously described
[1]. Creatinine clearance was calculated as creatinine ex-
cretion divided by serum creatinine concentration.
Histology and morphometric analysis
The kidneys were immersion-fixed in 10% neutral-
buffered formalin and embedded in paraffin. Sections 4
lm thick were stained with periodic acid-Schiff (PAS).
A computer-assisted image analysis system was used to
quantify glomerulosclerosis and tubular atrophy (tubu-
lar dilation and tubule cell height) in the renal cortex, as
described previously [1, 22]. Interstitial volume was de-
termined by two blinded observers who assessed 20 high
powered sections/animal. Interstitial volume was graded
by evaluating the percentage of interstitial fibrosis per
field on a scale of 0 to 4 [23]: 0, normal; 0.5, small focal
areas of fibrosis per field; 1, fibrosis involving less than
10% of the cortical interstitium; 2, involvement of up
10% to 25% of the cortical interstitium; 3, involvement
of 25% to 50% of the cortical interstitium; and 4, ex-
tensive fibrosis involving more than 50% of the cortical
interstitium.
Immunohistochemistry
Frozen sections were cut at 5 lm, fixed with cold
acetone at 10 minutes and blocked with 0.3% H2O2
for 10 minutes to eliminate endogenous peroxidase and
10% goat serum for 10 minutes to minimize nonspe-
cific antibody binding. Sections then were incubated with
monoclonal antibodies for 60 minutes, followed by bi-
otinylated goat antimouse immunoglobulin (Ig) poly-
clonal antibody (BD PharMingen, San Diego, CA USA)
and avidin-biotin-horseradish peroxidase complex for
30 minutes each. The slides were incubated with 3,3-
diaminobenzidine (DAB) tetrahydrochloride to produce
a dark brown-colored end product. The monoclonal anti-
bodies used were W3/25 for CD4+, OX-8 for CD8+, NDS-
61 for CD25+ cells, and CD68 for macrophages (Serotec,
Oxford, UK). Staining was quantitated by a blinded ob-
server counting 20 consecutive high power fields per an-
imal and expressed as cells per 400 × field.
Evaluation of antichemokine antibody in sera of
DNA-vaccinated rats
Anti-MCP-1 or anti-RANTES antibody titers (total Ig)
were determined by a direct enzyme-linked immunosor-
bent assay (ELISA) assay as described [21, 24]. Briefly, 96
wells of an Immulon 1 ELISA microtiter plate (Dynatech
Laboratories, Alexandria, VA, USA) were coated with
each recombinant rat chemokine MCP-1 and RANTES
(Chemicon, Temecula, CA, USA) at a concentration of
25 ng/well in 100 lL of coating buffer and reacted sequen-
tially with test rat sera, alkaline phosphatase–conjugated
sheep antirat Ig Fab fragments (Boehringer Mannheim,
GmbH, Mannheim, Germany) and substrate solution
[0.5% p-nitrophenyl phosphate (Sigma Chemical Co.) in
carbonate buffer, pH 9.6). Absorbance was read at 405
nm on an ELISA reader (Dynatech Laboratories). Trip-
licate sample optical densities were read at 405 nm, cor-
rected for a control sample of known strongly positive
serum optical density (i.e., sample optical density/control
positive serum optical density × 100). The anti-MCP-1
or anti-RANTES antibody titer of the control serum was
1:200.
Western blot
The specificity of autoantibodies was confirmed by
Western blot analysis according to the manufacturer’s in-
structions. Each recombinant rat chemokine MCP-1 and
RANTES (50 ng) was separated on 12% polyacrylamide
gel and transferred to polyvinlydine difluoride (PVDF)
membranes (NENTm Life Science Product, Boston, MA,
USA). The membranes were blocked overnight with
Tris-buffered saline containing 5% nonfat dry milk and
0.05% Tween 20 at 4◦C. One membrane was incubated
with serum (1:200 dilution) from chemokine DNA vac-
cinated rats for 1 hour and with rabbit antirat anti-
body (Dako, Carpinteria, CA, USA) for 1 hour. Another
membrane was incubated with rabbit antirat MCP-1
antibody (Chemicom) for 1 hour as a positive con-
trol. After incubation with antirabbit antibody conju-
gated with horseradish peroxidase (Dako), MCP-1 and
RANTES were detected by enhanced chemilumines-
cence (ECL) (Amersham Biosciences Pty Ltd., Bucking-
hamshire, UK).
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In vitro chemotaxis assay
The chemotaxis assay was performed in a 6-well cham-
ber (Corning Costar, New York, NY, USA). Recombi-
nant rat chemokine MCP-1 (10 ng/mL) and RANTES
(10 ng/mL) were added in RPMI 1640 with 0.5% bovine
serum albumin (BSA) and/or serum from DNA vacci-
nated rats in total volume of 2.6 mL and placed in the
lower wells. Freshly isolated rat splenic cells were incu-
bated in RPMI 1640 with 10% fetal calf serum (FCS)
overnight at 37◦C. The cells were harvested, washed three
times in PBS, and then suspended in RPMI 1640 with
0.5% BSA. Cell suspension of 1.5 mL at 1 × 107/mL
was added to the upper insert well, which was separated
from the lower well by 8 lm pore size, polycarbonate,
polyvinypyrolidone-free membranes. The chamber was
incubated for 4 hours at 37 ◦C in an atmosphere contain-
ing 5% CO2. The insert well was then carefully removed.
The cells that migrate to the lower well were counted us-
ing a light microscope. Approximately 10% of the cells
will migrate spontaneously (known as migrating cells on
negative control, 1.7 × 106 to 2 × 106 cells). The results
were expressed as cell migration where cell migration is
the number of migrating cells in the lower chamber af-
ter subtracting the number of migrating cells in medium
control with no added chemokines.
Blood white cell counting
Blood white cells were analyzed by a standard auto-
mated Coulter Counter.
Statistical analysis
The results are expressed as mean ± SD. Statistical
significance of difference between and among the groups
was made by one-way analysis of variance (ANOVA). A
value of P < 0.05 was considered significant.
RESULTS
High levels of MCP-1 and RANTES mRNA expression
in a kidney
As reported previously [6], the adriamycin nephropa-
thy rat model was characterized by massive pro-
teinuria immediately after adriamycin injection and
progressed to renal failure. In the adriamycin rat at 4 to
6 weeks, severe nephrotic syndrome, glomerular sclero-
sis, tubular atrophy, and interstitial fibrosis with massive
interstitial mononuclear cell infiltration were observed.
Expression of MCP-1 and RANTES mRNA in adri-
amycin nephropathy kidney was significantly increased in
adriamycin nephropathy kidney compared with the con-
trols (P < 0.001) (Fig. 1).
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Fig. 1. High levels of monocyte chemoattractant protein-1 (MCP-1)
and regulated upon activation, normal T-cell expressed and secreted
(RANTES) mRNA expression in adriamycin nephropathy (AN) kid-
ney measured by semiquantitative reverse transcription-polymerase
chain reaction (RT-PCR). All results are expressed as mean ratio of
chemokine gene densitometry score to 18S rRNA densitometry score
± SD (N = 5 per group). Expression of MCP-1 and RANTES mRNA
was significantly increased in adriamycin nephropathy kidney compared
with the controls (P < 0.001).
Chemokine DNA vaccination is protective in adriamycin
nephropathy
DNA vaccination encoding MCP-1 and RANTES sig-
nificantly reduced proteinuria from week 1 to week 4
postadriamycin administration (Fig. 2) compared with
AN and DV controls. There was no significant difference
in proteinuria between adriamycin nephropathy and con-
trol groups. Control rats injected with only PBS did not
develop proteinuria. Chemokine DNA vaccination had
no effect on proteinuria in the normal rats, as there was
no significant difference in proteinuria between PBS and
DNA vaccination alone groups at each time point.
Chemokine DNA vaccination significantly amelio-
rated renal dysfunction in rat adriamycin nephropathy.
Serum creatinine in the DNA vaccination group was sig-
nificantly lower than in the DNA vaccination control
group (47.6 ± 15.1 vs. 70.0 ± 14.8 umol/L) (P < 0.05
at week 2) (49.2 ± 9.7 vs. 70.0 ± 10.5 umol/L) (P <
0.05 at week 3) and the adriamycin nephropathy group
(81.0 ± 6.2 and 83.3 ± 8.6 umol/L) (P < 0.05 at weeks
2 and 3, respectively). Creatinine clearance in DNA vac-
cination group was significantly higher than in the DNA
vaccination control and adriamycin nephropathy groups
(P < 0.05) (Fig. 3) from week 2 to week 4 postadriamycin
administration. There was no significant difference in cre-
atinine clearance between adriamycin nephropathy and
DNA vaccination control groups. Normal rats injected
with only PBS did not develop renal failure. Chemokine
DNA vaccines had no effect on serum creatinine and cre-
atinine clearance in the normal rats.
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Fig. 2. DNA vaccination encoding monocyte chemoattractant protein-
1 (MCP-1) and regulated upon activation, normal T-cell expressed
and secreted (RANTES) significantly reduced proteinuria from week
1 to week 4 post adriamycin (ADR) administration compared with
adriamycin nephropathy and DNA vaccination controls (P< 0.05 or
P< 0.01). The rats were treated with DNA vaccination against MCP-
1 and RANTES in adriamycin nephropathy ( ); DNA vaccination
with empty pTarget vector as a control for vaccination in adriamycin
nephropathy (), adriamycin alone (•) and phosphate-buffered saline
only in normals as a control for adriamycin (). Mean ± SD.
Chemokine DNA vaccination significantly alleviated
the histologic manifestations of adriamycin nephropa-
thy at week 4 (Table 1). Light microscopic examination
revealed that glomeruli and tubules were only mildly
damaged at week 4 in the DNA vaccination group, as
compared with the DNA vaccination control and the adri-
amycin nephropathy groups (Fig. 4). Morphometric anal-
ysis showed much less glomerulosclerosis in the DNA
vaccination group than in the DNA vaccination control
and adriamycin nephropathy groups (P < 0.05). Most
tubules were intact in DNA vaccination group rats and
tubular atrophy was significantly alleviated by chemokine
DNA vaccination, in comparison with rats in the adri-
amycin nephropathy group and DNA vaccination con-
trol groups. Furthermore, vaccination with chemokine
reduced interstitial infiltrates in DNA vaccination group
in comparison to adriamycin nephropathy group and
DNA vaccination control group (P < 0.05). Morphologic
data are summarized in Table 1.
Examination of renal interstitial infiltrates in adri-
amycin nephropathy rats at 4 weeks demonstrated sig-
nificant infiltrates of macrophages (CD68), CD8+ and
CD4+ T cells, and CD25+ cells in renal interstitium as
compared with PBS control rats (P < 0.005), as shown
in Figure 5. Macrophages, CD8+ and CD4+ T cells, and
CD25+ cells in renal interstitium in the DNA vaccina-
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Fig. 3. DNA vaccination significantly improved creatinine clearance.
Creatinine clearance in DNA vaccination (DV) group was significantly
higher than in the DNA vaccination control (DV control) and adri-
amycin nephropathy (AN) groups from week 2 to week 4 post adri-
amycin (ADR) administration. PBS is phosphate-buffered saline group.
∗P < 0.05. Mean ± SD.
tion group were significantly less than in the adriamycin
nephropathy and DNA vaccination control groups (P <
0.001). There were no significant differences in staining
for these cell infiltrates in the interstitium between the
adriamycin nephropathy and DNA vaccination control
groups. These immunohistochemical data also are sum-
marized in Table 1.
Antichemokine antibodies produced by DNA
vaccination in vivo
We examined for the mechanism underlying the pro-
tection induced by chemokine DNA vaccination. To test
whether DNA vaccination with MCP-1 and RANTES
induced the production of autoantibodies against gene
products of each vaccinated DNA, we analyzed serum
samples of all animals from week 2 to week 4 for
specific autoantibodies against MCP-1 and RANTES
by ELISA. Rats vaccinated with chemokine DNA had
significantly higher titers of MCP-1 and RANTES au-
toantibody than rats in the adriamycin nephropathy,
DNA vaccination control, and PBS groups (P < 0.005),
as shown in Figure 6A. The specificity of those autoan-
tibodies was also confirmed by Western blot analysis as
shown in Figure 6B.
Antichemokine antibodies produced by DNA
vaccination blocked MCP-1 and RANTES-induced
chemotaxis in vitro
DNA vaccination generates both cellular and hu-
moral responses against products of a given construct.
To evaluate the possible contribution of antichemokine
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Table 1. Quantitation of morphology and immunohistochemistry
DNA vaccination Adriamycin Phosphate-buffered DNA vaccination
DNA vaccination control nephropathy saline alone
Morphology
Interstitial volume (0 to 4+) 1.3 ± 1.2a 2.8 ± 0.8 3.3 ± 0.6c 0 0
Glomerular sclerosis% 7.6 ± 4.2a 16.4 ± 6.1 19.3 ± 1.2c 0 0
Tubular diameter lm 34.6 ± 1.6a 31.5 ± 2.1 31.5 ± 0.6c 41.6 ± 0.9 42.3 ± 0.8
Tubular cell height lm 10.9 ± 0.3a 9.9 ± 0.9 10.3 ± 0.2c 12.8 ± 0.3 12.5 ± 0.2
Immunohistochemistry (cells/400 × field)
CD4+ cells 22.6 ± 13.3b 88.8 ± 18.2 84.9 ± 16.8d 1.1 ± 1.4 1.4 ± 1.2
CD8+ cells 8.3 ± 3.6b 37.7 ± 9.2 33.9 ± 5.1d 0.8 ± 0.2 0.4 ± 0.3
Macrophages (CD68+) 8.9 ± 3.9b 27.7 ± 7.3 29.6 ± 6.8d 1.8 ± 0.5 0.6 ± 0.4
CD25+ cells 0.42 ± 0.3b 4.5 ± 0.6 6.4 ± 2.2d 0.2 ± 0.1 0.1 ± 0.1
Value are expressed as mean ± SD.
aP < 0.05 compared with DNA vaccination control group and adriamycin nephropathy group; bP < 0.001 compared with DNA vaccination control group
and adriamycin nephropathy group; cP < 0.001 compared with phosphate-buffered saline group and DNA vaccination alone group; dP < 0.005 compared with
phosphate-buffered saline group and group DNA vaccination alone group.
Fig. 4. Chemokine DNA vaccination significantly reduced kidney
injury at week 4 post adriamycin administration, as shown on kid-
ney sections stained by periodic-acid Schiff (PAS) in DNA vaccination
group (A), DNA vaccination control group (B), adriamycin nephropa-
thy group (C), and phosphate-buffered saline group (D). Glomeruli
and tubules were only mildly damaged at 4 week in the DNA vaccina-
tion group, as compared with the DNA vaccaination control and the
adriamycin nephropathy groups (magnification 200×).
antibodies induced by chemokine DNA vaccination in
the protection of adriamycin nephropathy, we performed
an in vitro chemotaxis assay to evaluate induced an-
tichemokine antibodies inhibition of chemokine-induced
chemotaxis of splenic cells. The serum from MCP-1 and
RANTES DNA vaccinated rats significantly blocked
MCP-1 and RANTES-induced chemotaxis of splenic
cells as shown in Figure 7, whereas the serum from the
DNA vaccinated control group did not. Thus MCP-1 and
RANTES chemokine-specific autoantibodies generated
by naked DNA vaccination were neutralizing antibodies
that blocked recombinant MCP-1 and RANTES-induced
chemotaxis.
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Fig. 5. (continued)
Antichemokine antibodies produced by DNA
vaccination have no significant effect on white blood
cells in vivo
To determine whether antichemokine antibodies af-
fect white blood cells in vivo, we have measured circu-
lating white blood cells after DNA vaccination. There
was no significant difference in numbers of circulating
white blood cells in DNA vaccination group (8.6 ± 0.5 ×
109cells/L) compared to DNA vaccination control (8.9 ±
1.5 × 109cells/L) and PBS (8.1 ± 0.1 × 109cells/L) groups.
DISCUSSION
In the current study, we tested a novel therapeutic
approach, that DNA vaccination against MCP-1 and
RANTES would be protective in the rat adriamycin
nephropathy model of chronic proteinuric renal dis-
ease. The study showed that DNA vaccination targeting
the two C-C chemokines MCP-1 and RANTES signifi-
cantly reduced proteinuria, renal injury, and interstitial
infiltration.
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Fig. 5. Chemokine DNA vaccination
reduced interstitial infiltrates. (A)
Macrophages, CD8+ and CD4+ T-cells,
and CD25+ infiltrates in renal interstitium
in the DNA vaccination (DV) group were
significantly decreased compared with the
adriamycin nephropathy (AN) and DNA
vaccination control groups (DV ctrl). PBS
is phosphate-buffered saline group. ∗P <
0.001. Results are expressed as mean ± SD
of cells per 400 × field. (B) A representative
immunoperoxidase-stained kidney section
from the adriamycin nephropathy (AN) and
DNA vaccination (DV) group (magnification
200×).
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Fig. 6. (A) Antibody production measured by enzyme-linked immunosorbent assay (ELISA) in sera of adriamycin nephropathy (AN) rats following
C-C chemokine naked DNA vaccination. Rats vaccinated with chemokine DNA had significantly higher titers of monocyte chemoattractant
protein-1 (MCP-1) and regulated upon activation, normal T-cell expressed and secreted (RANTES) autoantibody than rats in the adriamycin
nephropathy, DNA vaccination control (DV ctrl) and phosphate-buffered saline (PSB) groups. ∗P < 0.005. (B) The specificity of autoantibodies to
bind recombinant rat MCP-1 (lane 1) and RANTES (lane 2) was also confirmed by Western blot analysis in which serum obtained from chemokine
DNA vaccinated rats (left) in comparison to the commercial antirat MCP-1 antibody (right).
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Fig. 7. The migration of splenic cells toward
monocyte chemoattractant protein-1 (MCP-
1) (left) and regulated upon activation, nor-
mal T-cell expressed and secreted (RANTES)
(right). The serum from MCP-1 and RANTES
DNA vaccinated rats significantly blocked
MCP-1 and RANTES-induced chemotaxis (P
<0.001 and P <0.05, respectlvely) in a chemo-
taxis assay. Results are expressed as mean of
triplicates ± SD.
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We previously showed upregulation of MCP-1 in rat
renal tubules [25, 26] and prominent expression of MCP-
1 and RANTES in adriamycin nephropathy kidney [6].
These chemokines are expressed by resident renal cells
and promote the recruitment of macrophages and T
cells into the kidney, and activation of these infiltrating
cells. Infiltrating leukocytes in turn become a major
source of local chemokine production, forming a posi-
tive amplification loop [5]. The correlation of chemokine
expression in the kidney with local accumulation of
macrophages and T cells, and renal damage suggest that
MCP-1 and RANTES-mediated renal damage may be
dependent on these effector cells. This hypothesis is sup-
ported by our finding that DNA vaccination targeting
MCP-1 and RANTES in adriamycin nephropathy sig-
nificantly reduced cell infiltrates, specifically T cells and
macrophages, and protected against renal injury. There
was also a reduction in CD25+ cells, as would be ex-
pected with a reduction in activated T cells in adriamycin
nephropathy kidney. MCP-1 and RANTES DNA vacci-
nation significantly reduced the severity of the disease in
adriamycin nephropathy, strongly supporting pathogenic
roles for these C-C chemokines (MCP-1 and RANTES)
in the influx of macrophages and T cells, and the resulting
renal injury in this model.
DNA vaccination, which induces immunization with
plasmid DNA encoding antigen, represents a novel
means of expressing antigen in vivo for the generation
of both cellular and humoral immune responses against
products of a given construct [27]. Naked DNA vaccines
promote a highly efficient protective immunity not only
against foreign antigens, such as microbes and tumors
but also self antigens, such as T-cell receptor Vb genes
[28], autologous cytokines [29–31], and chemokines [21,
32–34]. DNA vaccines appear to act as their own adju-
vant owing to the presence of immunostimulatory CpG
sequences in the backbone of the plasmid DNA that is
sufficient to activate antigen presentation potentially and
to elicit cellular immune responses and autoantibody re-
sponses [35, 36]. This is seen where T-cell receptor–based
naked DNA vaccination successfully prevented EAE by
generating suppressive T cells [28] and DNA vaccina-
tion against chemokine and cytokines proved effective in
EAE and arthritis by generating neutralizing chemokine
and cytokine antibody antibodies [21, 29–33]. In a pre-
vious study from our laboratory, T-cell receptor DNA
vaccination reduced proteinuria in Heymann nephritis
by generating specific autoantibodies that bind specific
T-cell receptors and block the activation of pathogenic
T-cells [37]. Since DNA vaccination elicits both cellular
and humoral responses against products of a given con-
struct, it is difficult to know which of these responses
contributed more to the protection of adriamycin
nephropathy in MCP-1 and RANTES DNA vaccinated
rats. It has been demonstrated previously that blocking
chemokine activity with neutralizing antibodies is pro-
tective in a variety of models of renal injury. For ex-
ample, neutralizing antibodies against MCP-1 reduced
infiltration of glomerular macrophages in rat anti-thy-1.1
nephritis [38]. Furthermore, treatment with MCP-1 an-
tibodies reduced proteinuria and monocyte infiltration
in rat nephrotoxic serum nephritis [11] and abrogated
crescent formation and leukocyte infiltration in murine
nephrotoxic nephritis [12]. DNA vaccination targeting
multiple chemokines has been used in other systems. For
example, DNA vaccination against macrophage inflam-
matory protein-1a (MIP-1a) and MCP-1 proved effective
in EAE [21, 33] by generating neutralizing chemokine
antibodies. In the current study, our data clearly show
that MCP-1 and RANTES DNA vaccination produced
significantly higher levels of specific antibodies to the
MCP-1 and RANTES that the DNA vaccine encoded.
We also demonstrated that these specific autoantibod-
ies neutralized MCP-1 and RANTES and blocked their
chemoattractant activity in a chemotaxis assay. There-
fore, we speculate that in our study antichemokine anti-
bodies produced following DNA vaccination contributed
to disease protection in DNA vaccinated rats.
A major limitation in treatment of chronic diseases
with neutralizing antibodies is their immunogenicity (that
is, the development of host antibodies against therapeu-
tic antibodies). In contrast, a major advantage of DNA
vaccines is induction of cellular or humoral immune re-
sponses to autologous antigen. In addition, when codeliv-
ered with plasmid-DNA encoding other molecules, there
is the possibility of enhancement or modulation of the
subsequent response to the DNA-encoded antigen [39].
For example, recent studies have demonstrated that DNA
vaccine encoding interleukin (IL)-5 modified to contain
a foreign CD4+ T-cell epitope is more effective than un-
modified vaccine against IL-5, in inducing and neutral-
izing polyclonal anti-IL-5 antibodies and ameliorating
experimental asthma [30]. We have also tested vaccina-
tion with MCP-1 alone in this model with no effect dis-
ease severity, even though autoantibody to MCP-1 was
induced. However, modifications that enhance the im-
munogenicity of the single chemokines may allow these
alone to be effective. In a recently completed study we
have shown that vaccination with modified MCP-1 was
protective in this model, with higher titer of autoanti-
body to MCP-1 than with unmodified MCP-1 vaccine
[abstract; Zheng G, Nephrology 9(Suppl 1):A21, 2004].
This new therapeutic approach can potentially be ap-
plied to target cell receptors, ligand molecules and cy-
tokines/chemokines in renal diseases as well.
CONCLUSION
Naked DNA vaccination against MCP-1 and RANTES
ameliorates the progression of disease in the rat adri-
amycin nephropathy model of chronic proteinuric re-
nal disease. The protective mechanism may involve the
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production of autoantibodies against MCP-1 and
RANTES, with consequent reduction in renal infiltration
by and activation of effector cells.
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